Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703)

Yihebali Chi(Chinese Academy of Medical Sciences & Peking Union Medical College), Jianqiang Cai(Chinese Academy of Medical Sciences & Peking Union Medical College), Yanhong Deng(Sun Yat-sen University), Guisheng Li(University of Shanghai for Science and Technology), Helong Zhang(Shanghai International Studies University), Yi Ba(Tianjin Medical University Cancer Institute and Hospital), Yongkun Sun(Chinese Academy of Medical Sciences & Peking Union Medical College), Yujuan Qi(Qinghai Provincial Peoples Hospital), Ying Cheng(Jilin Province Tumor Hospital), Jianhong Wang(Xijing Hospital), Jianping Xiong(Nanchang University), Yongqian Shu(Jiangsu Province Hospital), Xingwen Li(State Key Laboratory of Electrical Insulation and Power Equipment), Yigui Chen(Fujian Medical University), Minhui Wu(Yulin Normal University), Yong Tang(Chongqing Medical University), Yuxian Bai(Harbin Medical University), Jiang Liu(Sun Yat-sen University), Jin Li(Hainan Medical University), Yongqiang Li(Shandong University), Chunhong Hu(Central South University), Donglin Wang(Shandong University), Jian Dong(Anyang Hospital of Traditional Chinese Medicine), Jianming Xu(Chinese PLA General Hospital), Jifeng Feng(Zhejiang Cancer Hospital), Zhendong Chen(Anhui Medical University), Qiong Wu(Zhejiang Chinese Medical University), Xiuwen Wang(Second Hospital of Shandong University), Baoli Qin(Liaoning Cancer Hospital & Institute), Jufeng Wang(Henan Cancer Hospital), Da Jiang(The Third Affiliated Hospital of Zhejiang Chinese Medical University), Jianfeng Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Chengxue Dang(First Affiliated Hospital of Xi'an Jiaotong University), Nong Xu(First Affiliated Hospital Zhejiang University), Yiye Wan(Jiangxi Provincial Cancer Hospital)
The Oncologist
June 9, 2021
10.1002/onco.13857
Cited by 64

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k